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Increased Expression of Vascular Endothelial Growth
Factor and Angiogenesis in the Early Stage of
Multistep Hepatocarcinogenesis
Young Nyun Park, MD; Young-Bae Kim, MD; Kyung Moo Yang, MD; Chanil Park, MD
● Background.—Hepatocellular carcinoma (HCC) is
known to receive its blood supply principally from the he-
patic arteries. Recent studies have reported differences in
the vascular supply, especially arterial supply among low-
and high-grade dysplastic nodules (DNs) (also referred to
as adenomatous hyperplasia and macroregenerative nod-
ules) and HCCs. Increased expression of vascular endothe-
lial growth factor (VEGF) has been reported in HCC. In
addition, VEGF may play an important role in the early
phases of hepatocarcinogenesis.
Methods.—We immunohistochemically stained 7 low-
grade DNs, 8 high-grade DNs, 11 early HCCs, 17 small
HCCs, and 21 advanced HCCs with antibodies against
VEGF, a-smooth muscle actin (to identify unpaired arter-
ies, ie, arteries not accompanied by bile ducts, indicative
of angiogenesis), CD34 (as a marker of sinusoidal capillar-
ization), and proliferation cell nuclear antigen.
Results.—Expression of VEGF was found in the hepato-
cytes and HCC cells. The degree of VEGF expression in-
creased gradually according to the stepwise development
of hepatocarcinogenesis. It was higher in high-grade DNs
and early HCCs than in low-grade DNs. The hepatocytes
and HCC cells adjacent to peliosis and fibrous septa
showed stronger VEGF expression. Angiogenesis, unpaired
arteries, and sinusoidal capillarization developed from
low-grade DNs and gradually increased. It was highest in
HCCs. The proliferation cell nuclear antigen labeling in-
dexes of hepatocytes and HCC cells also increased gradu-
ally as hepatocarcinogenesis progressed. Small HCCs
showed a higher status of neoangiogenesis and cell prolif-
eration activity than advanced HCCs. The degree of VEGF
expression was correlated with angiogenesis and cell pro-
liferation activity.
Conclusion.—We conclude that VEGF plays a significant
role in angiogenesis, growth, and development of HCC.
(Arch Pathol Lab Med. 2000;124:1061–1065)
It has been demonstrated that angiogenesis is critical fortumor growth and that, without the ability to recruit
new blood vessels, it is unlikely that most tumors would
ever grow beyond a limited size.1,2 It is, therefore, sug-
gested that tumors may continuously produce certain me-
diators that induce angiogenesis, permitting tumor cell
proliferation and expansion.
Vascular endothelial growth factor (VEGF), identical to
vascular permeability factor,3–5 was originally discovered
as a tumor-secreted protein, and its role in tumor devel-
opment has been investigated.6,7 It is considered to play
an important role in tumor biology in at least 2 ways: as
a vascular permeability factor and/or endothelial growth
factor. As a potent permeability factor, VEGF promotes
extravasation of plasma fibrinogen, leading to the forma-
tion of a fibrin network that serves as a substratum for cell
migration during angiogenesis. In addition, as an endo-
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thelial growth factor, VEGF stimulates endothelial cell
proliferation and is likely to induce the formation of new
blood vessels.8
Recently, distinctly hepatocellular nodules have been
found in chronic liver disease and cirrhosis, and they have
been considered to be premalignant lesions. These nod-
ules are referred to variously as dysplastic nodules (DNs),
adenomatous hyperplasia, or macroregenerative nodules.9–12 The
DNs might be the first step of hepatocarcinogenesis, sub-
sequently developing into a hepatocellular carcinoma
(HCC) nodule through low-grade DN, high-grade DN,
and early HCC.
Since HCC is a distinctively hypervascular tumor and
angiogenesis is important in hepatocarcinogenesis,13–15
and also since increased expression of VEGF has been re-
ported in HCC,16–20 we studied the degree of VEGF ex-
pression and its relationship to angiogenesis and the pro-
liferation activity of hepatocytes and HCC cells in low-
grade DNs, high-grade DNs, early HCCs, small HCCs,
and advanced HCCs to understand the role of VEGF in
the early stage of hepatocarcinogenesis. To evaluate angio-
genesis, we examined the development of unpaired arter-
ies unaccompanied by bile duct and sinusoidal capillari-
zation.
MATERIALS AND METHODS
We studied 7 low-grade DNs, 8 high-grade DNs, 11 early
HCCs, 17 small HCCs, and 21 advanced HCCs, which were cho-
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Table 1. Semiquantitative Assessment of Vascular








































* DN indicates dysplastic nodule; HCC, hepatocellular carcinoma.
sen from the resected liver pathology files of Yonsei University
Medical Center between 1991 and 1997. Low-grade DN showed
mild atypia, and in high-grade DN atypia was moderate but in-
sufficient for the diagnosis of malignant neoplasm.9 Early HCC
was defined as high-grade DN with microscopic foci of well-
differentiated HCC.21 The HCCs that were less than 3 cm in di-
ameter were classified as small HCCs, and the HCCs that were
more than 3 cm in diameter were classified as advanced HCCs.
The differentiation of HCC was evaluated by the Edmondson-
Steiner grade system. All the early HCCs were grade I. Small
HCCs included 13 cases of grade II and 4 cases of grade III. In
advanced HCCs, 10 cases were grade II and 11 cases were grade
III.
All these lesions were obtained from 53 patients (6 men and 1
woman; mean age, 51.4 years), and the number of lesions per
patient varied from 1 to 4. The causes of chronic liver disease
were hepatitis B virus in 39 cases and hepatitis C virus in 7 cases,
whereas 7 cases showed negative reaction to a serologic test for
both hepatitis virus B and C. The nonneoplastic liver showed
cirrhosis in 36 cases.
All tissue sections were fixed in 10% buffered formaldehyde
solution, processed by routine methods, and stained with he-
matoxylin-eosin. Immunohistochemical staining was carried out
as described previously.13 The primary antibodies used were
polyclonal antibody to VEGF (Santa Cruz Biotechnology, Santa
Cruz, Calif) at a dilution of 1:200, monoclonal antibody to alpha-
smooth muscle actin (Dako Corporation, Carpenteria, Calif) at a
dilution of 1:50, monoclonal antibody to CD34 (Q BEND 10) (Bio-
genex, San Ramon, Calif) at a dilution of 1:10, and proliferation
cell nuclear antigen (PCNA) (Dako) at a dilution of 1:50.
The expression of VEGF was semiquantitatively evaluated as
follows: those having positive staining in less than 5% were re-
garded as 11, between 5% and 15% as 21, between 15% and
50% as 31, and greater than 50% as 41. Arteries of angiogenesis,
so-called unpaired arteries, were defined as those not accompa-
nied by bile duct. The number of unpaired arteries was counted
in 10 random fields of 3100 magnification, and it was semiquan-
titatively evaluated as follows: 11, 1 to 5 unpaired arteries; 21,
6 to 15 unpaired arteries; 31, 16 to 50 unpaired arteries; and 41,
more than 50 unpaired arteries. Sinusoidal capillarization of an-
giogenesis was evaluated by the degree of CD34 expression as
follows: 11, staining of some endothelial cells occupying ap-
proximately less than 10% of the sinusoidal liver cell surface; 21,
staining of endothelial cells occupying approximately 10% to 30%
of the sinusoidal liver cell surface; 31, staining of endothelial
cells occupying approximately 30% to 50% of the sinusoidal liver
cell surface; and 41, staining of endothelial cells occupying more
than 50% of the sinusoidal liver cell surface. Areas of the Glisson
capsule, fibrous septa, collapsed parenchyma, and necrotic area
were excluded from evaluation of angiogenesis. The proliferation
activity was evaluated as PCNA labeling indexes (LIs). At least
500 nuclei were selected randomly using a monoclonal eye-piece
grid and a mechanical stage to avoid recounting. The PCNA-LIs
were expressed as a percentage of positive nuclei per all nuclei
counted.
Statistical analysis was performed using x2 test, Fisher exact
test, and linear regression test as deemed appropriate.
RESULTS
Expression of VEGF in Multistep Hepatocarcinogenesis
Expression of VEGF was found in hepatocytes and tu-
mor cells. It was semiquantitatively evaluated and sum-
marized in Table 1.
The degree of VEGF expression increased gradually ac-
cording to the stepwise development of hepatocarcinogen-
esis (Figure 1). All the low-grade DNs showed very weak
(11) expression of VEGF. High-grade DNs and early
HCCs showed relatively higher VEGF expression than
low-grade DNs. Two of 8 high-grade DNs and 2 of 11
early HCCs showed 31 VEGF expression. The degree of
VEGF expression was more intense in the hepatocytes ad-
jacent to peliosis. In small and advanced HCCs, the degree
of VEGF expression was relatively higher than in DNs.
Four of 17 small HCCs and 4 of 21 advanced HCCs
showed strong (41) expression of VEGF. The degree of
VEGF expression was more intense in the tumor cells ad-
jacent to necrosis and fibrous septa. There was no signif-
icant difference of VEGF expression according to the dif-
ferentiation of HCCs.
Expression of VEGF in the nonneoplastic portion of the
liver was very weak (11 or not appreciable), whereas the
compressed and inflamed liver tissue adjacent to the tu-
mor capsule showed 11 or 21 VEGF expression.
Angiogenesis of Development of Unpaired Arteries and
Sinusoidal Capillarization and Its Relationship to VEGF
Expression in Multistep Hepatocarcinogenesis
The development of unpaired arteries was semiquanti-
tatively evaluated and is summarized in Table 2. The de-
velopment of unpaired arteries started in low-grade DNs,
and it gradually increased according to the stepwise pro-
gression of hepatocarcinogenesis (Figure 2). The number
of unpaired arteries of high-grade DNs and early HCCs
was significantly higher than those of low-grade DNs (P
5 .01). In HCCs, the number of unpaired arteries mark-
edly increased, and small HCCs showed the highest num-
ber of unpaired arteries. Twelve of 17 small HCCs showed
more than 50 unpaired arteries per 10 3 100 fields, where-
as 8 of 21 advanced HCCs showed less than 6 unpaired
arteries per 10 3 100 fields, and all of them showed a thick
trabecular pattern with patent sinusoid.
The degree of VEGF expression increased as the un-
paired arteries developed. The degree of VEGF expression
and the number of unpaired arteries showed a significant
correlation (P 5 .0103, r 5 0.3209).
To assess the sinusoidal capillarization, CD34 expres-
sion of sinusoidal endothelial cells was evaluated (Table
3). CD34 expression gradually increased as multistep he-
patocarcinogenesis progressed (Figure 3). The degree of
CD34 expression was significantly higher in high-grade
DNs than in low-grade DNs (P 5 .004). In low-grade DNs,
CD34 expression was confined mainly to the outer region
with periportal and peripheral pattern. CD34 expression
became more diffuse, and this pattern was not retained in
high-grade DNs and more advanced lesions of multistep
hepatocarcinogenesis. Both small and advanced HCCs
showed a significantly higher degree of CD34 expression
than in high-grade DNs and early HCCs (P 5 .018). In
advanced HCCs, all 8 cases with thick trabecular and pat-
ent sinusoid pattern showed 41 CD34 expression. Their
VEGF expression was 11 in 3 cases and 21 in 5 cases.
Sinusoidal capillarization did not show a significant dif-
ference according to the differentiation of HCC.
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Figure 1. Vascular endothelial growth factor (VEGF) expression in multistep hepatocarcinogenesis. Expression of VEGF is very weak in low-grade
dysplastic nodules (A, 3200) and intermediate in high-grade dysplastic nodules (B, 3100) and diffuse and strong in hepatocellular carcinoma (C,
3200).
Figure 2. Development of unpaired arteries in multistep hepatocarcinogeneis. Immunohistochemical stain for a smooth muscle actin showing 2
unpaired arteries in low-grade dysplastic nodules (A), more developed status of unpaired arteries in high-grade dysplastic nodules (B), and numerous
unpaired arteries in hepatocellular carcinoma (C) (3100).
Figure 3. Sinusoidal capillarization in multistep hepatocarcinogenesis. Immunohistochemical stain for CD34 showing peripheral and periportal
sinusoidal capillarization in low-grade dysplastic nodules (A), more diffuse sinusoidal capillarization in high-grade dysplastic nodules (B), and
widespread sinusoidal capillarization in hepatocellular carcinoma (C) (3100).









































* DN indicates dysplastic nodule; HCC, hepatocellular carcinoma.
The degree of VEGF expression increased as sinusoidal
capillarization developed in multistep hepatocarcinogen-
esis, and there was a significant correlation between them
(P , .0001, r 5 0.4932).
Cell Proliferation Activity and Its Relationship to VEGF
Expression in Multistep Hepatocarcinogenesis
The range of PCNA-LI was 1 to 9 with a mean of 4.2 in
low-grade DNs, 4 to 12 with a mean of 7.9 in high-grade
DNs, 3 to 26 with a mean of 9.3 in early HCCs, 18 to 80
with a mean of 39.9 in small HCCs, and 7 to 70 with a
mean of 27.6 in advanced HCCs. The PCNA-LI increased
gradually according to stepwise development of hepato-
carcinogenesis. The PCNA-LIs of small HCCs were sig-
nificantly higher than those of early HCCs (P 5 .0001) and
advanced HCCs (P 5 .015). There was no significant dif-
ference of PCNA-LI according to the differentiation of
HCCs.
The PCNA-LI showed a significant correlation to the de-
gree of VEGF expression (P 5 .0054, r 5 0.3671). In ad-
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Table 3. Semiquantitative Assessment of CD341









































* DN indicates dysplastic nodule; HCC, hepatocellular carcinoma.
dition, PCNA-LI showed a significant correlation to the
degree of angiogenesis, the development of unpaired ar-
tery (P 5 .0034, r 5 0.3853), and sinusoidal capillarization
(P , .0001, r 5 0.5240).
COMMENT
In recent years, many studies have been performed to
find premalignant lesions in the human liver, and DNs
are considered likely candidates.9–12 It is suggested that
DNs may be the first step of multistep hepatocarcinogen-
esis and that they develop into HCC nodules probably
through high-grade DNs and subsequently into early
HCCs, at least in HCC cases associated with chronic liver
disease.21
In physiologically normal tissue, angiogenesis is unre-
markable. Whereas neoplasms require the development of
neovascularization,12,22 angiogenesis is suggested to be in-
duced by the local activation of genes encoding angiogenic
factors such as VEGF.3–6 It has been demonstrated that
messenger RNA and the protein of VEGF are expressed
and produced in a wide variety of human neoplasms and
are strongly correlated with tumor-associated angiogene-
sis.6,7 Also, VEGF is reported to be important in angio-
genesis of HCCs, and the VEGF gene is reported to be
transcribed, expressed, and secreted by HCC cells.16–20
This study demonstrated that VEGF expression and an-
giogenesis had already occurred in the preneoplastic le-
sion of DNs. The degree of VEGF expression and angio-
genesis gradually increased according to the progression
of multistep hepatocarcinogenesis, and there was a signif-
icant correlation between them. This finding suggests that
VEGF plays an important role in angiogenesis of multi-
step hepatocarcinogenesis starting from an early stage.
Immunohistochemical stain in this study showed that
VEGF is mainly expressed by hepatocytes and HCC cells.
It, therefore, seems reasonable to suggest that the exces-
sive VEGF produced and secreted by hepatocytes and
HCC cells may subsequently act on endothelial cells, re-
sulting in the growth of new blood vessels and the cap-
illarization of sinusoidal endothelial cells. Such paracrine
communication between hepatocytes and endothelial cells
in the liver via VEGF and its receptor has previously been
reported.23
The tumor cells adjacent to peliosis or necrosis showed
a stronger expression of VEGF in this study, and hypoxia
is considered to enhance the expression of VEGF.24 Ex-
pression of VEGF messenger RNA has been reported to
be locally elevated in the area adjacent to tumor necro-
sis.18,25,26 In this study, VEGF expression was also found in
compressed and inflamed nonneoplastic liver tissue ad-
jacent to the tumor capsule as previously reported.16–18
This suggests that VEGF expression is regulated by in-
flammatory cytokines released from infiltrating inflam-
matory cells. Several cytokines, such as basic fibroblast
growth factor, transforming growth factor a, epidermal
growth factor, transforming growth factor b, and platelet-
derived growth factor, have been reported to act cooper-
atively and could enhance VEGF expression.27–29
Cell proliferation activities in this study increased ac-
cording to the progression of multistep hepatocarcinogen-
esis, as in previous reports.30,31 They also showed signifi-
cant correlation to the degree of VEGF expression and an-
giogenesis. Thus, VEGF expression is considered to con-
tribute to the growth advantage in hepatocarcinogenesis
through angiogenesis. The association of VEGF with tu-
mor growth essentially supports the biological importance
of angiogenic peptide in hepatocarcinogenesis as shown
by in vitro culture studies.20,22
Small HCCs had the highest number of unpaired arter-
ies and the highest PCNA-LI. Expression of VEGF was 41
in 4 of 17 small HCCs in contrast to 1 of 21 advanced
HCCs. Expression of VEGF has been reported to be an
important angiogenic factor for the growth of small breast
carcinoma in vivo; however, it is not essential after the
tumor size becomes larger.32 Usually, the turnover time of
endothelial cells is 50 to 60 hours, whereas that of neo-
plastic cells is 22 hours. Therefore, the different rates of
endothelial cell and neoplastic cell turnover seem to make
the intercapillary distance increase as the tumor size in-
creases.33 Thus, small HCC is considered to be the highest
developed stage of angiogenesis in multistep hepatocar-
cinogenesis.
Many consider VEGF one of the key factors promoting
the production of tumor vessels in hepatocarcinogenesis.
However, the degree of VEGF expression was variable in
the cases of HCCs, and 30% of HCCs showed VEGF ex-
pression in less than 5% of the tumor cells. As a result,
VEGF may not be the only factor involved in the angio-
genesis of hepatocarcinogenesis in these cases, and other
angiogenic factors may contribute to the development of
tumor angiogenesis.
At present, our knowledge about the mechanism of
VEGF overexpression and its participation in multistep
hepatocarcinogenesis remains limited. However, the data
presented herein suggest that VEGF is strongly involved
in the development of angiogenesis of multistep hepato-
carcinogenesis starting from the early stage and that it
contributes to the growth advantage of hepatocytes via
angiogenesis.
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